AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

pharmafile | March 13, 2020 | News story | Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure 

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined with Lynparza (olaparib), failed to meet its main goal in clinical trials.

In the US National Cancer Institute-sponsored study, the combo failed to meet its primary endpoint of statistically significant improvement in progression-free survival (PFS) in the intent-to-treat population compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer.

Despite this, the combo’s safety profile was found to be in line with previous data.

“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” said José Baselga, Executive Vice President, Oncology R&D. “We will work closely with NRG Oncology and the NCI to review the full results to inform our ongoing research.”

Ovarian cancer is the eighth most deadly cancer in the world for women. Cediranib fights the disease by inhibiting the expansion of tumours through blocking the growth of the blood vessels that sustain them.

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after …


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …

Latest content